Solventum (MEX:SOLV) Debt-to-Revenue : 0.97 (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Solventum Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Solventum's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was MXN4,171 Mil. Solventum's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was MXN162,883 Mil. Solventum's annualized Revenue for the quarter that ended in Dec. 2024 was MXN173,102 Mil. Solventum's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 0.97.

Solventum Debt-to-Revenue Historical Data

The historical data trend for Solventum's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Solventum Debt-to-Revenue Chart

Solventum Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Revenue

0.97

Solventum Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Revenue	Get a 7-Day Free Trial						-	1.03	1.00	0.97	0.97

Competitive Comparison of Solventum's Debt-to-Revenue

For the Medical Instruments & Supplies subindustry, Solventum's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Solventum's Debt-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Solventum's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Solventum's Debt-to-Revenue falls into.

Save Embed

;

Save Embed

;

Solventum Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Solventum's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(4171.14	+	162883.017)	/	172142.948
	=	0.97

Solventum's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(4171.14	+	162883.017)	/	173102.308
	=	0.97

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.

Solventum Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Solventum's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Solventum Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Solventum Corp (MEX:SOLV) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

SOLV:USA KB7:Germany

Address

2510 Conway Avenue East, 3M Center, Building 275-6W, Maplewood, MN, USA, 55144

Website

https://www.solventum.com/en-us/home

Solventum Corp is a healthcare company developing, manufacturing, and commercializing a portfolio of solutions that leverage deep material science, data science, and digital capabilities to address critical customer and patient needs. The company has four operating segments: MedSurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The company generates the majority of its revenue from the MedSurg segment, which provides wound care and surgical solutions that are intended to accelerate healing, prevent complications, and lower the total cost of care globally.